Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spike glycoprotein S1 receptor-binding domain (RBD)
- Target
- RBD
- Molecular classification
- Glycoprotein, Receptor Binding Domain
01
Overview
The spike glycoprotein (S) of SARS-CoV-2 contains the S1 subunit, which includes the receptor binding domain (RBD). The RBD is critical for recognizing and binding to human angiotensin-converting enzyme 2 (ACE2) receptors on host cells, initiating viral attachment and subsequent membrane fusion required for entry. The RBD is a major target for therapeutic antibodies and small-molecule inhibitors designed to block ACE2 interaction. It is also highly immunogenic, eliciting strong neutralizing antibody responses during natural infection or vaccination, making it a key target for vaccine development. Mutations in this region can significantly affect binding affinity, transmissibility, immune escape, and pathogenicity.
- Other names
- SARS-CoV-2 Spike RBDSpike S1 RBDS1 Receptor Binding Domain
02
Mechanism of action
Block ACE2 interaction
03
Biological functions
Receptor bindingViral entryImmune recognition
04
Disease associations
InfectionCOVID-19
05
Safety considerations
Antigenic variation leading to immune escapePotential for altered binding affinity and pathogenicity due to mutations
06
Interacting drugs
Therapeutic antibodies
1 more in the full profile.
Beyond the preview
Go deeper on Spike glycoprotein S1 receptor-binding domain (RBD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spike glycoprotein S1 receptor-binding domain (RBD).